SCHEMBL303641

SCHEMBL303641

c1cnnc(N2CCNCC2)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLD1 Q13393 2/20 0.59
BPTF Q12830 2/20 0.53
ALDH1A1 P00352 3/20 0.51
HTR3E A5X5Y0 3/20 0.51
HTR3B O95264 3/20 0.51
HTR3A P46098 3/20 0.51
HTR3D Q70Z44 3/20 0.51
HTR3C Q8WXA8 3/20 0.51
KDM4E B2RXH2 2/20 0.46
ADRB1 P08588 2/20 0.46
HTR2C P28335 2/20 0.46
SLC6A4 P31645 2/20 0.46
USP2 O75604 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
HTR1A P08908 1/20 0.46
MAPK1 P28482 1/20 0.46
HTR7 P34969 1/20 0.46
HTT P42858 1/20 0.46
HTR6 P50406 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29999093 1.00 PLD1 (0.59) PLD1BPTFALDH1A1HTR3EHTR3B
Hydrochloric Acid SCHEMBL29701046 0.98 PLD1 (0.58) PLD1BPTFALDH1A1HTR3EHTR3B
Hydrochloric Acid SCHEMBL23123869 0.98 PLD1 (0.58) PLD1BPTFALDH1A1HTR3EHTR3B
Hydrochloric Acid SCHEMBL4812837 0.98 PLD1 (0.58) PLD1BPTFALDH1A1HTR3EHTR3B
SCHEMBL5656510 0.93 CHRNB2 (0.54) PLD1BPTFALDH1A1HTR3EHTR3B
Biphenyl SCHEMBL27705049 0.92 SLC6A7 (0.57) PLD1BPTFALDH1A1HTR3EHTR3B
SCHEMBL28078001 0.83 ADRB1 (0.46) PLD1ALDH1A1HTR3EHTR3BHTR3A
SCHEMBL31005942 0.82 SLC6A7 (0.49) ALDH1A1KDM4ECYP1A2MAPK1HSD17B10
SCHEMBL12607645 0.82 SLC6A7 (0.49) ALDH1A1KDM4ECYP1A2MAPK1HSD17B10
SCHEMBL27276203 0.80 SLC6A7 (0.40) PLD1BPTFALDH1A1HTR3EHTR3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104046246-B The chemical-mechanical planarization of tungsten-containing substrate 气体产品与化学公司 2016-06-15 CN claimed
US-20140273458-A1 Chemical Mechanical Planarization for Tungsten-Containing Substrates AIR PRODUCTS AND CHEMICALS, INC. (US) 2014-09-18 US claimed
EP-2779217-A2 Chemical mechanical planarization for tungsten-containing substrates AIR PRODUCTS AND CHEMICALS, INC. (US) 2014-09-17 EP claimed
CN-104046246-A Chemical Mechanical Planarization for Tungsten-Containing Substrates AIR PROD & CHEM 2014-09-17 CN claimed
EP-4739684-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS Janssen Pharmaceutica NV (BE) 2026-05-13 EP disclosed
EP-4739682-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS Janssen Pharmaceutica NV (BE) 2026-05-13 EP disclosed
US-20250388589-A1 TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF DANATLAS PHARMACEUTICALS CO LTD (CN) 2025-12-25 US disclosed
US-20250352542-A1 TRPV2 CHANNEL BLOCKERS AND USE THEREOF ICHILOV TECH LTD. (IL) 2025-11-20 US disclosed
CN-119947711-A Organogels for sustained drug delivery, methods of preparation and uses thereof 视尔普斯眼科公司 2025-05-06 CN disclosed
US-12275727-B2 Compound containing structure of a five-membered heteroaromatic ring, pharmaceutical compositions thereof and applications thereof 280 BIO, INC. (US) 2025-04-15 US disclosed
CN-119816492-A TRPV2 channel blocker and use thereof 伊契洛夫科技有限公司 2025-04-11 CN disclosed
WO-2025054132-A1 ANTIBACTERIAL COMPOUNDS ARREPATH, INC. (US) 2025-03-13 WO disclosed
US-5157035-A Viricides JANSSEN PHARMACEUTICA N. V. (BE) 1992-10-20 US disclosed
US-5100893-A Viricides, effective against picorna virus, durability JANSSEN PHARMACEUTICA N.V. (BE) 1992-03-31 US disclosed
CN-1052857-A The preparation method of the pyridazine amine that antipicornaviral is used JANSSEN PHARMACEUTICA NV (BE) 1991-07-10 CN disclosed
EP-0435381-A1 Antipicornaviral pyridazinamines JANSSEN PHARMACEUTICA N.V. (BE) 1991-07-03 EP disclosed
EP-0156433-B1 ANTI-VIRALLY ACTIVE PYRIDAZINAMINES JANSSEN PHARMACEUTICA N.V. (BE) 1991-02-27 EP disclosed
EP-0211457-A2 Novel (4-substituted-piperazinyl)pyridazines JANSSEN PHARMACEUTICA N.V. (BE) 1987-02-25 EP disclosed
CN-86105558-A The preparation method of new (4-replaces-piperazinyl) pyridazine class 1987-01-28 CN disclosed
EP-0156433-A2 Anti-virally active pyridazinamines JANSSEN PHARMACEUTICA N.V. (BE) 1985-10-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12275727-B2 Compound containing structure of a five-membered heteroaromatic ring, pharmaceutical compositions thereof and applications thereof PARG, CYP3A5, CYP11B1 PLD1 4576/4885BPTF 798/4885ALDH1A1 749/4885
US-20250352542-A1 TRPV2 CHANNEL BLOCKERS AND USE THEREOF TRPV2, TRPV1, TRPA1 PLD1 3611/4885BPTF 3122/4885ALDH1A1 3552/4885
US-20250388589-A1 TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF CYP4A11, CYP11B1, CYP2D6 PLD1 2939/4885BPTF 4739/4885ALDH1A1 1726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.